Literature DB >> 29524704

Endoscopic Endonasal Surgery Treatment Strategies for Invasive Pituitary Adenoma: Analysis of Four Approaches.

Yang Ji-Hu1, Huang Guo-Dong2, Ji Tao1, Wang Hai-Dong1, Liu Yu-Fei1, Guo Jian1, Li Zhen1, Li Wei-Ping1.   

Abstract

OBJECTIVE: To explore the surgical methods and clinical effect of endoscopic endonasal approaches for the treatment of invasive pituitary adenomas (IPAs).
METHODS: A retrospective analysis was made of the clinical data of 74 patients (75 procedures) with IPAs treated by different endoscopic endonasal approaches at the Department of Neurosurgery, The First Affiliated Hospital of Shenzhen University from May 2014 to August 2017. The data include clinical manifestation, imaging features, surgical methods and complications, resection rate, cure rate, prognosis, and complications in different Knosp classifications and Hardy stages. The transcavernous approach was used in 47 patients, the lateral-cavernous approach was used in 14 patients, the tuberculum sella planum approach was used in 8 patients, and the diaphragma sellae open or dorsum sellae cut approach was used in 6 patients.
RESULTS: The gross total resection (GTR) rate was 70.7% (53 patients) and tumor residue rate was 29.3% (22 patients). GTR rate for pituitary adenoma according to Knosp classification was 89.3% in grade 3 and 28.6% in grade 4. The biology cure rate was 75.0% and 23.8%, respectively. There was significance between them (P < 0.05). In addition, the GTR rate of Hardy stage was 90.5% in stage C, 90.0% in stage D, 26.1% in stage E, and the biology cure rate was 80.1%, 75.0%, and 13.0%, respectively. There was significance among them (P < 0.05) Postoperative severe complications included 9 patients (12.0%) with cerebrospinal fluid leaks, 26 patients (34.7%)with electrolyte imbalance, 36 patients (48.0%) with transient diabetes insipidus, 22 patients (29.3%) with hypopituitarism, 2 patients (2.7%) with permanent hypopituitarism, and 2 patients (2.7%)with epistaxis. The follow-up lasted 2-41 months (average, 19.3 months). No patient experienced recurrence after GTR, 1 patient undergoing subtotal experienced recurrence and underwent reoperation, 3 patients underwent postoperative Gamma Knife treatment, and 2 patients with refractory IPA were given temozolomide and metformin chemotherapy.
CONCLUSIONS: According to the invasiveness of IPA, choosing the appropriate endoscopic surgical approach is helpful in removing tumors and reducing complications.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Endoscopic; Invasive pituitary adenomas; Surgical approaches; Treatment outcome

Year:  2018        PMID: 29524704     DOI: 10.1016/j.wneu.2018.02.162

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

Review 1.  Recent Advances of the Hippo/YAP Signaling Pathway in Brain Development and Glioma.

Authors:  Taohui Ouyang; Wei Meng; Meihua Li; Tao Hong; Na Zhang
Journal:  Cell Mol Neurobiol       Date:  2019-11-25       Impact factor: 5.046

2.  Association of NM23 polymorphisms and clinicopathological features and recurrence of invasive pituitary adenomas.

Authors:  Hua Wang; Wenyuan Sang
Journal:  Pituitary       Date:  2020-04       Impact factor: 4.107

3.  LncRNA XIST depletion prevents cancer progression in invasive pituitary neuroendocrine tumor by inhibiting bFGF via upregulation of microRNA-424-5p.

Authors:  Kai Zhou; Shaoshan Li; Guojia Du; Yandong Fan; Pengfei Wu; Hongjie Sun; Tingrong Zhang
Journal:  Onco Targets Ther       Date:  2019-09-02       Impact factor: 4.147

4.  Radiological Knosp, Revised-Knosp, and Hardy-Wilson Classifications for the Prediction of Surgical Outcomes in the Endoscopic Endonasal Surgery of Pituitary Adenomas: Study of 228 Cases.

Authors:  Marta Araujo-Castro; Alberto Acitores Cancela; Carlos Vior; Eider Pascual-Corrales; Víctor Rodríguez Berrocal
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

5.  Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone.

Authors:  Xirui Wang; Changwei Hu; Yabin Li; Baowen Ren; Gangfeng Yin
Journal:  J Oncol       Date:  2022-03-21       Impact factor: 4.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.